Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69012T3059
Total Employee Number:
17Description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -1.32 | |||||
Debt-to-Equity | -0.94 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -47.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33 | |||||
3-Year EPS without NRI Growth Rate | 21.3 | |||||
3-Year FCF Growth Rate | 34.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 56.02 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 151.74 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.81 | |||||
9-Day RSI | 42.34 | |||||
14-Day RSI | 49.41 | |||||
3-1 Month Momentum % | 327.03 | |||||
6-1 Month Momentum % | 203.85 | |||||
12-1 Month Momentum % | -27.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.54 | |||||
Quick Ratio | 0.45 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 851.05 | |||||
Days Sales Outstanding | 1670.26 | |||||
Days Payable | 2341.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -68 | |||||
Shareholder Yield % | -17.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -361.75 | |||||
Operating Margin % | -18245.48 | |||||
Net Margin % | -18360.54 | |||||
EBITDA Margin % | -18698.49 | |||||
FCF Margin % | -14170.18 | |||||
OCF Margin % | -14170.18 | |||||
ROA % | -304.23 | |||||
ROIC % | -236.68 | |||||
3-Year ROIIC % | -11.64 | |||||
ROC (Joel Greenblatt) % | -27618.56 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 67.62 | |||||
EV-to-EBIT | -4.58 | |||||
EV-to-EBITDA | -4.59 | |||||
EV-to-Revenue | 858.36 | |||||
EV-to-Forward-Revenue | 3.64 | |||||
EV-to-FCF | -6.06 | |||||
Earnings Yield (Greenblatt) % | -21.83 | |||||
FCF Yield % | -17.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OTLK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.332 | ||
| EPS (TTM) ($) | -1.17 | ||
| Beta | 0.662 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 257.26 | ||
| 14-Day RSI | 49.41 | ||
| 14-Day ATR ($) | 0.181588 | ||
| 20-Day SMA ($) | 1.581 | ||
| 12-1 Month Momentum % | -27.52 | ||
| 52-Week Range ($) | 0.1611 - 3.39 | ||
| Shares Outstanding (Mil) | 187 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Outlook Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-18 | In 150 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-18 | In 150 days | ||
| Third quarter earnings results for 2026 | 2026-08-14 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-05-15 | 0.23 (-1.10%) | ||
| General meeting for 2026 | 2026-03-10 09:00 | 0.45 (+9.17%) | ||
| First quarter earnings results for 2026 | 2026-02-17 | 0.49 (+8.60%) | ||
| Annual report for 2025 | 2025-12-19 | 2.07 (-9.61%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-19 | 2.07 (-9.61%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-02 10:00 | 1.86 (+4.49%) | ||
| Third quarter earnings results for 2025 | 2025-08-14 | 2.13 (+1.43%) |
Show
Entries
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(OTLK)'s stock price today?
The current price of OTLK is $1.42. The 52 week high of OTLK is $3.39 and 52 week low is $0.16.
When is next earnings date of Outlook Therapeutics Inc(OTLK)?
The next earnings date of Outlook Therapeutics Inc(OTLK) is 2026-08-14 Est..
Does Outlook Therapeutics Inc(OTLK) pay dividends? If so, how much?
Outlook Therapeutics Inc(OTLK) does not pay dividend.
Guru Commentaries on NAS:OTLK
No articles.
Press Release
Articles on Outlook Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers